Imexpharm Corp Cash Flow Quality Index
Imexpharm Corp cash flow quality index. Imexpharm Corp (IMP) has a Cash Flow Quality Index of 0.59x as of June 2026. Operating cash flow of ₫55.75 Billion is below net income of ₫93.93 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore Imexpharm Corp (IMP) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Imexpharm Corp (2019–2025)
Cash flow quality index of Imexpharm Corp from 2019 to 2025. Historical Cash Flow Quality Index for Imexpharm Corp across 7 annual periods. Values consistently above 1.0x indicate high-quality earnings. See IMP equity financing ratio to measure how much of total assets are equity-financed.
Imexpharm Corp Cash Flow Quality Index by Year (2019–2025)
Imexpharm Corp cash flow quality index by year from 2019 to 2025. Year-by-year earnings quality comparison for Imexpharm Corp. For the full cash flow conversion analysis, see Imexpharm Corp cash flow conversion.
| Year | Quality Index | Operating CF (VND) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.16x | ₫54.17 Billion | ₫349.14 Billion | ▼ -77.0% |
| 2024 | 0.67x | ₫216.27 Billion | ₫320.86 Billion | ▲ +598.9% |
| 2023 | -0.14x | ₫-40.47 Billion | ₫299.56 Billion | ▼ -108.3% |
| 2022 | 1.62x | ₫378.60 Billion | ₫233.96 Billion | ▲ +30.3% |
| 2021 | 1.24x | ₫234.88 Billion | ₫189.09 Billion | ▲ +256.1% |
| 2020 | 0.35x | ₫73.15 Billion | ₫209.70 Billion | ▼ -14.9% |
| 2019 | 0.41x | ₫66.59 Billion | ₫162.39 Billion | — |